356 related articles for article (PubMed ID: 33934525)
1. The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC.
Tasoulas J; Lenze NR; Farquhar D; P Schrank T; Shen C; Shazib MA; Singer B; Patel S; Grilley Olson JE; Hayes DN; Gulley ML; Chera BS; Hackman T; Olshan AF; Weiss J; Sheth S
Cancer Med; 2021 May; 10(10):3231-3239. PubMed ID: 33934525
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
An Y; Park HS; Kelly JR; Stahl JM; Yarbrough WG; Burtness BA; Contessa JN; Decker RH; Koshy M; Husain ZA
Cancer; 2017 Jul; 123(14):2762-2772. PubMed ID: 28323338
[TBL] [Abstract][Full Text] [Related]
3. Evaluating Adjuvant Therapy With Chemoradiation vs Radiation Alone for Patients With HPV-Negative N2a Head and Neck Cancer.
Yan F; Li H; Kaczmar JM; Sharma AK; Day TA; Neskey DM; Pipkorn P; Zenga J; Graboyes EM
JAMA Otolaryngol Head Neck Surg; 2020 Dec; 146(12):1109-1119. PubMed ID: 32790830
[TBL] [Abstract][Full Text] [Related]
4. Microscopic Extranodal Extension in HPV-Negative Head and Neck Cancer and the Role of Adjuvant Chemoradiation.
Yan F; Li H; de Almeida JR; Kaczmar JM; Pipkorn P; Zenga J; Richardson MS; Neskey DM; Sharma AK; Day TA; Graboyes EM
Otolaryngol Head Neck Surg; 2021 Oct; 165(4):536-549. PubMed ID: 33618570
[TBL] [Abstract][Full Text] [Related]
5. Primary surgery for human papillomavirus-associated oropharyngeal cancer: Survival outcomes with or without adjuvant treatment.
Cramer JD; Ferris RL; Kim S; Duvvuri U
Oral Oncol; 2018 Dec; 87():170-176. PubMed ID: 30527235
[TBL] [Abstract][Full Text] [Related]
6. Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age.
Chen MM; Colevas AD; Megwalu U; Divi V
Oral Oncol; 2018 Sep; 84():71-75. PubMed ID: 30115479
[TBL] [Abstract][Full Text] [Related]
7. Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation.
Zumsteg ZS; Luu M; Kim S; Tighiouart M; Mita A; Scher KS; Lu DJ; Shiao SL; Mallen-St Clair J; Ho AS
Ann Oncol; 2019 Jan; 30(1):76-84. PubMed ID: 30395159
[TBL] [Abstract][Full Text] [Related]
8. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
[TBL] [Abstract][Full Text] [Related]
9. Risk of Pathologic Extranodal Extension and Other Adverse Features After Transoral Robotic Surgery in Patients With HPV-Positive Oropharynx Cancer.
Zebolsky AL; George E; Gulati A; Wai KC; Carpenter P; Van Zante A; Ha PK; Heaton CM; Ryan WR
JAMA Otolaryngol Head Neck Surg; 2021 Dec; 147(12):1080-1088. PubMed ID: 34673904
[TBL] [Abstract][Full Text] [Related]
10. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
11. Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification.
Yoshida EJ; Luu M; David JM; Kim S; Mita A; Scher K; Shiao SL; Tighiouart M; Ho AS; Zumsteg ZS
Head Neck; 2018 Jun; 40(6):1228-1236. PubMed ID: 29417700
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of neoadjuvant chemotherapy and transoral endoscopic surgery with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck.
Weiss JM; Grilley-Olson JE; Deal AM; Zevallos JP; Chera BS; Paul J; Knowles MF; Usenko D; Weissler MC; Patel S; Hayes DN; Hackman T
Cancer; 2018 Jul; 124(14):2986-2992. PubMed ID: 29741773
[TBL] [Abstract][Full Text] [Related]
13. Association of Surgical Margin Distance With Survival in Patients With Resected Head and Neck Squamous Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial.
Sunkara PR; Graff JT; Cramer JD
JAMA Otolaryngol Head Neck Surg; 2023 Apr; 149(4):317-326. PubMed ID: 36821132
[TBL] [Abstract][Full Text] [Related]
14. Surgically Treated Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck: Outcome Predictors and the Role of Adjuvant Radiation Therapy.
Kampel L; Dorman A; Horowitz G; Fliss DM; Gutfeld O; Muhanna N
Ann Otol Rhinol Laryngol; 2021 Sep; 130(9):1016-1023. PubMed ID: 33514267
[TBL] [Abstract][Full Text] [Related]
15. Assessment of adjuvant therapy in resected head and neck cancer with high-risk features.
Ajmani GS; Nocon CC; Wang CH; Bhayani MK
Oral Oncol; 2017 Nov; 74():15-20. PubMed ID: 29103745
[TBL] [Abstract][Full Text] [Related]
16. Intratumor heterogeneity could inform the use and type of postoperative adjuvant therapy in patients with head and neck squamous cell carcinoma.
Mroz EA; Patel KB; Rocco JW
Cancer; 2020 Jan; 126(9):1895-1904. PubMed ID: 32083741
[TBL] [Abstract][Full Text] [Related]
17. Association of Core Biopsy With Extranodal Extension in Surgically Treated Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Zhu VL; Rand DR; Arnold KE; Pagedar NA; Bayon R; Buchakjian MR
JAMA Otolaryngol Head Neck Surg; 2023 Nov; 149(11):955-960. PubMed ID: 37433026
[TBL] [Abstract][Full Text] [Related]
18. Lymph node ratio as a prognostic factor for survival in patients with head and neck squamous cell carcinoma.
Sano D; Yabuki K; Takahashi H; Arai Y; Chiba Y; Tanabe T; Nishimura G; Oridate N
Auris Nasus Larynx; 2018 Aug; 45(4):846-853. PubMed ID: 29203318
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.
Ferris RL; Geiger JL; Trivedi S; Schmitt NC; Heron DE; Johnson JT; Kim S; Duvvuri U; Clump DA; Bauman JE; Ohr JP; Gooding WE; Argiris A
Ann Oncol; 2016 Dec; 27(12):2257-2262. PubMed ID: 27733374
[TBL] [Abstract][Full Text] [Related]
20. Role of adjuvant chemoradiotherapy in T4N0 stage IV head and neck cancer: A National Cancer Database analysis.
Kirke DN; Qureshi MM; Kamran SC; Ezzat W; Jalisi S; Salama A; Everett PC; Truong MT
Head Neck; 2018 Jun; 40(6):1174-1184. PubMed ID: 29417687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
